Gland Pharma Ltd - Company Profile
Powered by 
All the data and insights you need on Gland Pharma Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Gland Pharma Ltd Strategy Report
- Understand Gland Pharma Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gland Pharma Ltd (Gland Pharma) develops and manufactures active pharmaceutical ingredients. The company's products include injectables, prefilled syringes, vials, ampoules, ophthalmic solutions, lyophilized vials, and long-acting injectables, suspensions and hormonal products. It offers heparin sodium injection, enoxaparin sodium injection, rocuronium bromide injection and daptomycin injection, among others. Gland Pharma’s therapeutic categories include anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, fertility supplements and antagonists, among others. Its facilities are located in Hyderabad and Visakhapatnam, India. Gland Pharma is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Survey No.143-148,150&151, Near Gandimaisamma 'X' Roads, D.P Pally, Dundigal Gandimaisamma Manda, Hyderabad, Telangana, 500043
Website
glandpharma.com
Telephone
91 40 30510999
No of Employees
4,585
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLAND (NSE)
Revenue (2022)
$461.9M
-17.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-35.5%
(2022 vs 2021)
Market Cap*
$3.4B
Net Profit Margin (2022)
XYZ
-21.7%
(2022 vs 2021)
* As of and is in US$
Gland Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| APIs | Contract Manufacturing |
| Injectables | Out-licensing of Products |
| Vials | Contract Research and Development |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In February, the company announced its plans to invest INR4 billion in Genome Valley, near Hyderabad. |
| 2022 | Contracts/Agreements | In November, the company entered into an agreement to acquire Cenexi Group. |
| 2021 | Regulatory Approval | In October, the company secured the US FDA approval for its Sugammadex Injection. |
Competitor Comparison
| Key Parameters | Gland Pharma Ltd | Sun Pharmaceutical Industries Ltd | IPCA Laboratories Ltd | Abbott India Ltd | Ajanta Pharma Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Hyderabad | Mumbai | Mumbai | Mumbai | Mumbai |
| State/Province | Telangana | Maharashtra | Maharashtra | Maharashtra | Maharashtra |
| No. of Employees | 4,585 | 41,000 | 16,167 | 3,700 | 7,713 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Srinivas Sadu | Director; Chief Executive Officer; Managing Director | Executive Board | 2019 | 53 |
| Ravi Shekhar Mitra | Chief Financial Officer | Senior Management | 2019 | 46 |
| KVGK Raju | Chief Technology Officer | Senior Management | - | 71 |
| Sampath Kumar Pallerlamudi | Company Secretary and Compliance Officer | Senior Management | - | 42 |
| C S Venkatesan | Senior Vice President - Research and Development | Senior Management | - | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer